Fig. 4.

Non-selective vs. selective angiogenesis blockers. The receptors for selective angiogenic ligands (e.g., Scg3) are expressed only on the diseased but not normal endothelium, whereas the receptors for non-selective angiogenic factors (e.g., VEGF) are expressed on both diseased and normal endothelium. Selective angiogenesis blockers preferentially exert therapeutic activity on diseased vessels with minimal adverse effects on normal vessels. In contrast, non-selective angiogenesis blockers have therapeutic and detrimental effects on diseased and normal vasculature simultaneously